全文获取类型
收费全文 | 4395篇 |
免费 | 218篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 344篇 |
妇产科学 | 77篇 |
基础医学 | 353篇 |
口腔科学 | 144篇 |
临床医学 | 278篇 |
内科学 | 1367篇 |
皮肤病学 | 67篇 |
神经病学 | 273篇 |
特种医学 | 110篇 |
外科学 | 643篇 |
综合类 | 74篇 |
一般理论 | 1篇 |
预防医学 | 109篇 |
眼科学 | 155篇 |
药学 | 315篇 |
中国医学 | 19篇 |
肿瘤学 | 252篇 |
出版年
2024年 | 5篇 |
2023年 | 43篇 |
2022年 | 103篇 |
2021年 | 183篇 |
2020年 | 115篇 |
2019年 | 170篇 |
2018年 | 225篇 |
2017年 | 127篇 |
2016年 | 181篇 |
2015年 | 145篇 |
2014年 | 217篇 |
2013年 | 261篇 |
2012年 | 364篇 |
2011年 | 377篇 |
2010年 | 225篇 |
2009年 | 168篇 |
2008年 | 284篇 |
2007年 | 300篇 |
2006年 | 275篇 |
2005年 | 199篇 |
2004年 | 199篇 |
2003年 | 154篇 |
2002年 | 133篇 |
2001年 | 24篇 |
2000年 | 21篇 |
1999年 | 15篇 |
1998年 | 18篇 |
1997年 | 12篇 |
1996年 | 13篇 |
1995年 | 13篇 |
1994年 | 14篇 |
1993年 | 6篇 |
1992年 | 8篇 |
1991年 | 5篇 |
1990年 | 2篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1973年 | 2篇 |
1971年 | 1篇 |
排序方式: 共有4643条查询结果,搜索用时 31 毫秒
71.
72.
Yangyang R. Yu MD Jimmy Espinoza MD Deepak K. Mehta MD Sundeep G. Keswani MD Timothy C. Lee MD 《Journal of clinical ultrasound : JCU》2018,46(4):286-291
Fetus in fetu is an extremely rare congenital anomaly. We describe the perinatal diagnosis and management of a fetus with oropharyngeal and cervical fetus in fetu. High‐resolution ultrasonography with 3‐dimensional rendering can identify increased risks of airway obstruction in utero. Early identification allows a multidisciplinary team to be assembled for a scheduled ex utero intrapartum treatment procedure. 相似文献
73.
74.
75.
Kyung-Heup Ahn Andrew Sewell Jacqueline Elander Brian Pittman Mohini Ranganathan Handan Gunduz-Bruce John Krystal Deepak Cyril D'Souza 《Neuropsychopharmacology》2015,40(12):2822-2831
Some schizophrenia patients are more sensitive to amphetamine (AMPH)-induced exacerbations in psychosis–an effect that correlates with higher striatal dopamine release. This enhanced vulnerability may be related to gamma-aminobutyric acid (GABA) deficits observed in schizophrenia. We hypothesized that a pharmacologically induced GABA deficit would create vulnerability to the psychotomimetic effects to the ‘subthreshold'' dose of AMPH in healthy subjects, which by itself would not induce clinically significant increase in positive symptoms. To test this hypothesis, a GABA deficit was induced by intravenous infusion of iomazenil (IOM; 3.7 μg/kg), an antagonist and partial inverse agonist of benzodiazepine receptor. A subthreshold dose of AMPH (0.1 mg/kg) was administered by intravenous infusion. Healthy subjects received placebo IOM followed by placebo AMPH, active IOM followed by placebo AMPH, placebo IOM followed by active AMPH, and active IOM followed by active AMPH in a randomized, double-blind crossover design over 4 test days. Twelve healthy subjects who had a subclinical response to active AMPH alone were included in the analysis. Psychotomimetic effects (Positive and Negative Syndrome Scale (PANSS)), perceptual alterations (Clinician Administered Dissociative Symptoms Scale (CADSS)), and subjective effects (visual analog scale) were captured before and after the administration of drugs. IOM significantly augmented AMPH-induced peak changes in PANSS positive symptom subscale and both subjective and objective CADSS scores. There were no pharmacokinetic interactions. In conclusion, GABA deficits increased vulnerability to amphetamine-induced psychosis-relevant effects in healthy subjects, suggesting that pre-existing GABA deficits may explain why a subgroup of schizophrenia patients are vulnerable to AMPH. 相似文献
76.
Franchi Francesco Schneider David J. Prats Jayne Fan Weihong Rollini Fabiana Been Latonya Taatjes-Sommer Heidi S. Bhatt Deepak L. Deliargyris Efthymios N. Angiolillo Dominick J. 《Journal of thrombosis and thrombolysis》2022,54(3):373-381
Journal of Thrombosis and Thrombolysis - Low dose enteric-coated aspirin (EC-ASA) is routinely used for secondary cardiovascular event prevention. However, absorption of EC tablets is poor, which... 相似文献
77.
Ritika Sharma Manu Jamwal Hari Kishan Senee Varun Uppal Jasbir Kaur Hira Parveen Bose Narender Kumar Deepak Bansal Amita Trehan Pankaj Malhotra Jasmina Ahluwalia Reena Das 《Indian journal of hematology & blood transfusion》2021,37(3):414
Glanzmann thrombasthenia (GT) is an autosomal recessive platelet function disorder characterized by mucocutaneous bleeding as the most common clinical phenotype. Patients with GT have normal platelet counts, platelet morphology but reduced platelet aggregation in response to various agonists. Homozygosity or compound heterozygosity for variants in the ITGA2B/ITGB3 genes is the genetic basis for GT. Establishing a molecular diagnosis is definitive and is important for predictive testing. Using multi-gene panels is an accurate, faster, and cost-effective mode as compared to Sanger sequencing in large genes. We used a targeted resequencing based approach to identify pathogenic variants in eight cases in seven families. These variants were validated using Sanger sequencing in patients as well as family members and were predicted probably pathogenic using in-silico prediction tools. The variants include three missense (3/7 = 43%) (ITGA2B:c.1028 T > C, ITGA2B:c.1186G > A, ITGB3:c.1388G > C), two deletions (ITGA2B:c.559delG, ITGA2B:c.3092delT), one duplication (ITGA2B:c.1424_1427dupAGGT) and nonsense variant (ITGA2B:c.2578C > T, p.Gln860Ter). Except for one case which was compound heterozygous, the rest of the cases were homozygous. We found two novel variants that are reported for the first time in GT. The targeted resequencing based approach revealed varied genetic variants in North Indian patients, including two novels ones. The high yield of our panel indicates its suitability for usage in larger cohorts for the genetic diagnosis of GT patients. This approach is cost-effective and less cumbersome as compared to Sanger sequencing for these large size genes with multiple exons. The information so obtained is helpful in prenatal testing, carrier analysis, and genetic counseling. 相似文献
78.
Aspirin and clopidogrel resistance: an emerging clinical entity. 总被引:28,自引:0,他引:28
Antiplatelet therapy is a cornerstone of cardiovascular medicine. Aspirin and clopidogrel have emerged as critical therapies in the treatment of cardiovascular disease. Despite their efficacy, patients on these medications continue to suffer complications. Millions of patients are currently on low-dose antiplatelet therapy but it is unknown how many of these patients are under-treated or on the wrong medication. Aspirin and clopidogrel resistance are emerging clinical entities with potentially severe consequences such as recurrent myocardial infarction, stroke, or death. The mechanism of resistance remains incompletely defined, but there are specific clinical, cellular, and genetic factors that influence therapeutic failure. These factors range from physicians who fail to prescribe these medications despite appropriate indications to polymorphisms of platelet membrane glycoproteins. Rapid and accurate diagnosis of antiplatelet resistance also remains an issue as new bedside tests are developed. By understanding the mechanism of therapeutic failure and by improving the diagnosis of this clinical entity, a new era of individualized antiplatelet therapy may arise with routine measurements of platelet activity in the same way that cholesterol, blood pressure, and blood sugar are followed, thus improving the care for millions of people. 相似文献
79.
Agal S Baijal R Pramanik S Patel N Gupte P Kamani P Amarapurkar D 《Journal of gastroenterology and hepatology》2005,20(11):1745-1752
BACKGROUND: Hepatotoxicity to antituberculosis therapy (ATT) poses a major challenge. This often results in inadequate therapy. The risk of fulminant hepatic failure and mortality is high once icteric hepatitis develops. There is no consensus on monitoring protocols and for the reintroduction of ATT. METHODS: All patients (from the Department of Internal Medicine and Gastroenterology, Jagjivanram Hospital and the Department of Gastroenterology, Bombay Hospital, Mumbai, India) with a diagnosis of tuberculosis, who were to receive ATT during the study period, were included in the present study for prospective periodic laboratory monitoring for the development of hepatotoxicity. Those patients who developed hepatotoxicity formed Group A (n = 21), whereas those who did not develop hepatotoxicity were included in Group C (n = 179). For the purpose of comparison with Group A, all the patients who presented directly with ATT induced hepatotoxicity during the study period were categorized as Group B (n = 24). Group A and B were further studied after normalization of liver functions for sequential reintroduction with therapeutic doses at a weekly interval. RESULTS: In Group A, 66.6% (14 patients) of the patients were diagnosed in the asymptomatic period. Seven patients had symptomatic hepatitis, but none had icteric illness. There were no mortalities in Group A. In contrast, all the patients in Group B had symptomatic hepatitis (75% icteric hepatitis). There was a mortality rate of 16.6% (four patients). Of the 41 patients from Groups A and B who survived, reintroduction was successful in 38/39 (97.4%). In the remaining two patients who were in Group B, reintroduction was not attempted because of decompensated liver disease. CONCLUSIONS: Periodic laboratory monitoring is important in detecting hepatotoxicity at an early stage, thereby preventing mortality. Sequential reintroduction is often successful. 相似文献
80.
Mohammad Khalid Parvez Deepak Sehgal Shiv Kumar Sarin Seemi Farhat Basir Shahid Jameel 《World journal of gastroenterology : WJG》2006,12(19)
AIM: To evaluate the in vitro anti-HBV activity of recombinant human IFN-γ, alone and in combination with lamivudine.METHODS: A recombinant baculovirus-HBV/HepG2 culture system was developed which could support productive HBV infection in vitro. Expression of HBsAg and HBeAg in infected HepG2 culture medium was detected by commercial enzyme immunoassays. HBV DNA replication intermediates were detected in infected cells by Southern hybridization and viral DNA load was determined by dot hybridization.RESULTS: IFN-γ at 0.1 to 5 μg/L efficiently down regulated HBsAg expression in transduced HepG2 cells.At 5 μg/L, IFN-γ also suppressed HBV DNA replication in these cells. While treatment with a combination of lamivudine and IFN-γ showed no additive effect,sequential treatment first with lamivudine and then IFN-γ was found to be promising. In this culture system the best HBV suppression was observed with a pulse of 2 μmol/L lamivudine for two days, followed by 1 μg/L IFN-γ for another four days. Compared to treatment with lamivudine alone, the sequential use of 0.2 μmol/L lamivudine for two days, followed by 5 μg/L IFN-γ for six days showed a 72% reduction in HBV cccDNA pool.CONCLUSION: This in vitro study warrants further evaluation of a combination of IFN-γ and lamivudine,especially in IFN-α non-responder chronic hepatitis B patients. A reduced duration of lamivudine treatment would also restrict the emergence of drug-resistant HBV mutants. 相似文献